Skip to main content
  • Home
  •  Implementing Heart Failure Guidelines with Collaborative Care

Implementing Heart Failure Guidelines with Collaborative Care

  • Heart Failure

Available Credit:

  • Not accredited

Course Published On:

Course Expiry Date:

Implementing Heart Failure Guidelines with Collaborative Care
No ratings


This satellite symposium, presented and recorded at ESC 2023 in Amsterdam, by Prof Carolyn Lam (National Heart Centre Singapore, SG), provides an excellent opportunity to learn about the latest guideline recommendations in HFpEF and how to implement them effectively in clinical practice.


The panel of experts, including Dr Gianluigi Savarese (Karolinska Institute, Stockholm, SE), Dr Stephen Greene (Duke University School of Medicine, North Carolina, US), Prof Mark Petrie (University of Glasgow, Glasgow, UK) and Carys Barton (Imperial College Healthcare NHS Trust, London, UK) provide valuable insights into the challenges and barriers faced while adopting new guideline-directed medical therapy for heart failure patients. Collaborative care is an essential aspect of heart failure therapy and this session emphasises the significance of cross-functional teams in managing this condition.

Support Statement

This satellite symposium is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the content.

Target Audience

  • Cardiologists
  • Heart Failure Specialists
  • Primary Care Physicians
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
  • Apply latest guideline recommendations to patient cases
  • Describe barriers preventing early initiation of GDMT
  • Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
  • Identify the importance of the nurse/cross-functional team
Register now Log in





Session 1 Introduction and Part 1: Addressing New Guidelines 20 mins Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton
Session 2 Early / Rapid Initiation of GDMT 30 mins Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton
Session 3 Audience Q&A 10 mins Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton
Session 1.

Introduction and Part 1: Addressing New Guidelines

Duration: 20 mins

Speakers: Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton

Session 2.

Early / Rapid Initiation of GDMT

Duration: 30 mins

Speakers: Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton


Carolyn Lam

National Heart Centre Singapore Duke-NUS, Singapore

Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore.

View full profile


Mark Petrie

University of Glasgow, UK

Prof Mark Petrie is Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK. Prof Petrie started his studies as an undergraduate at Edinburgh University, before training in cardiology in Glasgow.

View full profile

Stephen J Greene

Duke University School of Medicine, North Carolina, US

Dr Stephen Greene is Assistant Professor in Advanced Heart Failure & Transplantation at The Duke University School of Medicine in Durham, North Carolina, US. 

View full profile

Gianluigi Savarese

Karolinska Institute, Stockholm, SE

Dr Gianluigi Savarese is currently an Associate Professor of Cardiology and Heart Failure Specialist at the Karolinska Institute in Stockholm, Sweden. 

View full profile
Carys Barton

Carys Barton

Imperial College Healthcare NHS Trust, London, UK

Carys Barton is a heart failure consultant nurse at Imperial College Healthcare NHS Trust in London, UK.

View full profile
This course is not accredited

Related Courses

A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure
  • Not accredited

Learning objectives

  • Recall guideline recommendations for the use of NT-proBNP in heart failure
  • Describe current practices in heart failure diagnosis and the impact on treatment outcomes
  • Develop an optimised approach to the timely diagnosis and management of heart failure
See more
The Advancing Management of Transthyretin Amyloidosis
  • 1.00 EBAC

Learning objectives

  • To differentiate ATTR phenotypes based on presenting signs and symptoms.
  • To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
  • To recall how to identify disease progression across ATTR-cm.
  • To describe the different disease modifying treatments for ATTR including novel agents.
See more
Overcoming the Challenges in Optimising GDMT in HF
  • Not accredited

Learning objectives

  • Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
  • Recognise barriers preventing the use of GDMT in current practice.
  • Identify strategies needed to drive implementation of GDMT in clinical practice.
See more
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Not accredited

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more
Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
  • 1.00 EBAC

Learning objectives

  • Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
  • Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
  • Select appropriate imaging modalities to facilitate accurate risk stratification
  • Stratify patients based on specific risk features and disease severity
  • Choose suitable treatment modalities for patients based on specific disease features and severity
See more
Incorporating GDMT and PRO Endpoints for Personalised HF Management
  • 1.00 EBAC

Learning objectives

  • Review current GDMT in HFrEF and HFpEF
  • Describe the relationship between initiation of GDMT and HF outcomes
  • Prescribe GDMT according to current international recommendations
  • Recall the elements of the Kansas City Cardiomyopathy Questionnaire
  • Describe the clinical studies that support the use of functional and QoL measures in practice
  • Initiate quality of life and functional improvement measures in routine practice
  • Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
  • Adopt shared decision-making with HF patients
See more
Changing Paradigms in Therapy to Unmet Needs
  • 1.00 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response 
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy 
  • Incorporate quality of life measures for assessing therapeutic efficacy in HF 
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice 
See more
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more
Making Gains in HFpEF: An Appraisal of Where We Are Now
  • Not accredited

Learning objectives

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
See more